1
40
3
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.21037/hbsn.2019.09.03" target="_blank" rel="noreferrer noopener">http://doi.org/10.21037/hbsn.2019.09.03</a>
Pages
152-169
Issue
2
Volume
9
ISSN
2304-3881 2304-3881
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<a href="http://neomed.idm.oclc.org/login?url=http://doi.org/10.21037/hbsn.2019.09.03" target="_blank" rel="noreferrer noopener">NEOMED Full-text Holding (if available) - Proxy DOI: 10.21037/hbsn.2019.09.03</a>
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Update Year & Number
June 2020 Update I
NEOMED College
NEOMED College of Medicine
NEOMED Department
Department of Integrative Medical Sciences
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease.
Publisher
An entity responsible for making the resource available
Hepatobiliary surgery and nutrition
Date
A point or period of time associated with an event in the lifecycle of the resource
2020
2020-04
Subject
The topic of the resource
alcoholic liver disease (ALD); bacterial translocation; Bile acid; binding protein; farnesoid X receptor (FXR); farnesoid-x-receptor; fatty liver; glucagon-like peptide-1; growth-factor 19; gut microbiota; microbiota; molecular-cloning; non-alcoholic steatohepatitis (NASH); non-alcoholic steatohepatitis (NASH); nuclear receptor; solute transporter-alpha
Creator
An entity primarily responsible for making the resource
Li Tiangang; Chiang John Y L
Description
An account of the resource
Bile acids are synthesized from cholesterol only in hepatocytes. Bile acids circulating in the enterohepatic system act as physiological detergent molecules to help solubilize biliary cholesterol and emulsify dietary lipids and fat-soluble vitamins in small intestine. Bile acids are signaling molecules that activate nuclear receptor farnesoid X receptor (FXR) and cell surface G protein-coupled receptor TGR5. FXR critically regulates bile acid homeostasis by mediating bile acid feedback inhibition of hepatic bile acid synthesis. In addition, bile acid-activated cellular signaling pathways regulate metabolic homeostasis, immunity, and cell proliferation in various metabolically active organs. In the small and large intestine, gut bacterial enzymes modify primary bile acids to generate secondary bile acids to help shape the bile acid pool composition and subsequent biological effects. In turn, bile acids exhibit anti-microbial properties and modulate gut microbiota to influence host metabolism and immunity. Currently, bile acid-based therapies including systemic and intestine-restricted FXR agonists, TGR5 agonists, fibroblast growth factor 19 analogue, intestine FXR antagonists, and intestine apical sodium-bile acid transporter (ASBT) inhibitors have been developed as promising treatments for non-alcoholic steatohepatitis (NASH). These pharmacological agents improved metabolic and inflammatory disorders via distinct mechanisms of action that are subjects of extensive research interest. More recently, human and experimental alcoholic liver disease (ALD) has been associated with disrupted bile acid homeostasis. In additional, new findings showed that targeting bile acid metabolism and signaling may be promising therapeutic approaches for treating ALD.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.21037/hbsn.2019.09.03" target="_blank" rel="noreferrer noopener">10.21037/hbsn.2019.09.03</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Format
The file format, physical medium, or dimensions of the resource
journalArticle
2020
alcoholic liver disease (ALD)
Bacterial Translocation
bile acid
binding protein
Chiang John Y L
Department of Integrative Medical Sciences
farnesoid X receptor (FXR)
farnesoid-x-receptor
Fatty Liver
glucagon-like peptide-1
growth-factor 19
gut microbiota
Hepatobiliary surgery and nutrition
Journal Article
journalArticle
June 2020 Update I
Li Tiangang
Microbiota
molecular-cloning
NEOMED College of Medicine
non-alcoholic steatohepatitis (NASH)
Nuclear Receptor
solute transporter-alpha
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.14309/01.ajg.0000706532.82398.af" target="_blank" rel="noreferrer noopener">http://doi.org/10.14309/01.ajg.0000706532.82398.af</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
S564-S565
Issue
S
Volume
115
ISSN
0002-9270
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<a href="http://neomed.idm.oclc.org/login?url=http://doi.org/10.14309/01.ajg.0000706532.82398.af" target="_blank" rel="noreferrer noopener">NEOMED Full-text Holding (if available) - Proxy DOI: 10.14309/01.ajg.0000706532.82398.af</a>
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Update Year & Number
February 2021 List
NEOMED College
NEOMED College of Pharmacy
NEOMED Department
Department of Pharmaceutical Sciences
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Role of Markers of Heavy Metal Metabolism in Identification of Hepatic Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD)
Date
A point or period of time associated with an event in the lifecycle of the resource
2020
2020-10
Subject
The topic of the resource
Oxidative stress; hepatic fibrosis; non-alcoholic fatty liver disease; Heavy Metals; non-alcoholic steatohepatitis (NASH)
Creator
An entity primarily responsible for making the resource
Aggarwal Manik;Mitchell B;Singh AD;Kasumov T;McCullough A
Description
An account of the resource
INTRODUCTION: Fibrosis & nonalcoholic steatohepatitis (NASH) are important predictors of long term prognosis in patients with non-alcoholic fatty liver disease (NAFLD). Oxidative stress (OS) has been shown to play a central role in progression of NAFLD, & changes in proteins associated with metal homeostasis may exacerbate OS. We investigated relationship of proteins related to transition metal metabolism with fibrosis in NAFLD. METHODS: Adult patients (>18y) who underwent liver biopsy for clinically suspected NAFLD at our institution were included. We retrospectively collected serum levels of ceruloplasmin (Cp), ferritin, iron, & transferrin saturation (Tsat) within 3 months of liver biopsy & calculated Cp/Tsat ratio (CT ratio) & Cp/Ferritin ratio (CF ratio). Histologic features were scored by an experienced pathologist using Non-alcoholic Steatohepatitis Clinical Research Network criteria. Fibrosis was staged as (0 - 4). Independent T test were used to compare the means & receiver operating characteristics (ROC) curves were plotted for assessing area under curve (AUC), sensitivity (Sn) & specificity (Sp). RESULTS: 174 patients were included in final analysis. The mean age of subjects was 48 y. Baseline features are depicted in Table 1. Biopsy proven NASH was seen in 61.5% of liver biopsies. No fibrosis was seen in 29.3% of liver biopsies & Stage 1, 2,3& 4 fibrosis were seen in 29.9%, 10.9%, 14.3% & 15.55% of samples. Mean Tsat was significantly higher (24.41% v/s 38.27%, P < 0.0001) & Cp (mg/dl) (27.82 v/s 24.91, P = 0.03) significantly lower between patients with advanced fibrosis (AF) (3-4) v/s early fibrosis (EF) (0-2). The mean CT ratio was also higher in patients with EF v/s AF (1.54 v/s 1.02, P = 0.01). The mean Tsat of patients with fibrosis v/s without fibrosis was higher (31.4% v/s 21.57% P < 0.005) however mean Cp (mg/dl) values were not significantly different (27.88 v/s 27.58, P = 0.42). The ROC curves show CF ratio (Figure 1) at a cut off of 0.10 had AUC = 0.61 (Sn = 70%, Sp = 52% P = 0.01) to detect any fibrosis & CT ratio (Figure 2) at a cut off 0.86 had AUC = 0.65 (Sn = 69%, Sp = 50% P = 0.002) for differentiating EF v/s AF. CONCLUSION: Our data reveals changes in ceruloplasmin: transferrin system, which decreases the content of toxic ions of Fe2+ in NAFLD. Tsat, Cp, CF ratio & CT ratio are useful non-invasive biomarkers in identifying NAFLD patients with fibrosis. Markers of heavy metal metabolism can spare patients from liver biopsies & can be potential therapeutic targets in future.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.14309/01.ajg.0000706532.82398.af" target="_blank" rel="noreferrer noopener">10.14309/01.ajg.0000706532.82398.af</a>
Format
The file format, physical medium, or dimensions of the resource
journalArticle
Publisher
An entity responsible for making the resource available
American Journal Of Gastroenterology
2020
Aggarwal Manik
American Journal of Gastroenterology
Department of Pharmaceutical Sciences
February 2021 List
Heavy Metals
hepatic fibrosis
journalArticle
Kasumov T
McCullough A
Mitchell B
NEOMED College of Pharmacy
non-alcoholic steatohepatitis (NASH)
Non-alcoholic Fatty Liver Disease
Oxidative Stress
Singh AD
-
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Articles Published in 2021
Creator
An entity primarily responsible for making the resource
Shelley Harrell
Publisher
An entity responsible for making the resource available
Shelley Harrell
Date
A point or period of time associated with an event in the lifecycle of the resource
2021
Description
An account of the resource
Items published in 2021
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<table width="91" style="border-collapse:collapse;width:68pt;"><colgroup><col width="91" style="width:68pt;" /></colgroup><tbody><tr style="height:15pt;"><td width="91" height="20" class="xl18" style="width:68pt;height:15pt;"><a href="http://doi.org/10.1016/j.ultrasmedbio.2021.06.002">http://doi.org/10.1016/j.ultrasmedbio.2021.06.002</a></td>
</tr></tbody></table>
NEOMED College
NEOMED College of Medicine
NEOMED Department
Department of Radiology
Update Year & Number
Jan to Aug list 2021
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Quantification of Liver Fat Content with Ultrasound: A WFUMB Position Paper.
Creator
An entity primarily responsible for making the resource
Ferraioli G; Berzigotti A; Barr RG; Choi BI; Cui XW; Dong Y; Gilja OH; Lee JY; Lee DH; Moriyasu F; Piscaglia F; Sugimoto K; Wong GL; Wong VW; Dietrich CF
Publisher
An entity responsible for making the resource available
Ultrasound in Medicine & Biology
Date
A point or period of time associated with an event in the lifecycle of the resource
2021
2021-08-24
Description
An account of the resource
New ultrasound methods that can be used to quantitatively assess liver fat content have recently been developed. These quantitative ultrasound (QUS) methods are based on the analysis of radiofrequency echoes detected by the transducer, allowing calculation of parameters for quantifying the fat in the liver. In this position paper, after a section dedicated to the importance of quantifying liver steatosis in patients with non-alcoholic fatty liver disease and another section dedicated to the assessment of liver fat with magnetic resonance, the current clinical studies performed using QUS are summarized. These new methods include spectral-based techniques and techniques based on envelope statistics. The spectral-based techniques that have been used in clinical studies are those estimating the attenuation coefficient and those estimating the backscatter coefficient. Clinical studies that have used tools based on the envelope statistics of the backscattered ultrasound are those performed by using the acoustic structure quantification or other parameters derived from it, such as the normalized local variance, and that performed by estimating the speed of sound. Experts’ opinions are reported.
Subject
The topic of the resource
The assessment of steatosis (liver fat content) is relevant in patients suspected of, or diagnosed with, chronic liver diseases. Steatosis is usually a diffuse process within the liver tissue, but a non-uniform distribution can sometimes be observed (focal fatty changes or zonal/regional steatosis, focal or segmental sparing).
Identifier
An unambiguous reference to the resource within a given context
<table width="91" style="border-collapse:collapse;width:68pt;"><colgroup><col width="91" style="width:68pt;" /></colgroup><tbody><tr style="height:15pt;"><td width="91" height="20" class="xl18" style="width:68pt;height:15pt;"><a href="http://doi.org/10.1016/j.ultrasmedbio.2021.06.002">http://doi.org/10.1016/j.ultrasmedbio.2021.06.002</a></td>
</tr></tbody></table>
Rights
Information about rights held in and over the resource
38; Biology. All rights reserved.
Format
The file format, physical medium, or dimensions of the resource
Journal Article
2021
Attenuation coefficient
Backscatter
controlled attenuation parameter
DISPERSION
non-alcoholic steatohepatitis (NASH)
Non-alcoholic Fatty Liver Disease
quantitative ultrasound
Speed of sound